Todd Simpson
Director/Board Member bij Washington Biotechnology & Biomedical Association
Profiel
Momenteel is Todd E. Simpson voorzitter voor Neoleukin Therapeutics, Inc. en Chief Financial Officer voor Seagen Inc. De heer Simpson zit ook in de raad van bestuur van Cascadian Therapeutics, Inc. en de Washington Biotechnology & Biomedical Association. In zijn vorige loopbaan was hij CFO, VP-Finance & Administration bij Vericel Corp., Treasurer bij Integra LifeSciences Holdings Corp. en Chief Financial Officer & Vice President van Telios Pharmaceuticals, Inc. (een dochteronderneming van Integra LifeSciences Holdings Corp.), CFO & VP-Finance & Administration bij AmpliPhi Biosciences Corp. en Principal bij Ernst & Young LLP. Hij behaalde een bachelorgraad aan de Oregon State University.
Actieve functies van Todd Simpson
Bedrijven | Functie | Begin |
---|---|---|
Washington Biotechnology & Biomedical Association | Director/Board Member | 25-04-2017 |
Eerdere bekende functies van Todd Simpson
Bedrijven | Functie | Einde |
---|---|---|
SEAGEN INC. | Director of Finance/CFO | 14-12-2022 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01-10-2005 |
VERICEL CORPORATION | Director of Finance/CFO | 01-10-2001 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01-10-2001 |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Treasurer | 01-12-1995 |
Opleiding van Todd Simpson
Oregon State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Health Technology |
VERICEL CORPORATION | Health Technology |
Bedrijven in privébezit | 8 |
---|---|
Telios Pharmaceuticals, Inc.
Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Integra LifeSciences Holdings Corp., Telios Pharmaceuticals, Inc. is a pharmaceutical company focused on research. The private company is based in San Diego, CA. The company was founded by Iain David Dukes, Erkki Ruoslahti. Telios Pharmaceuticals was acquired by Integra LifeSciences Holdings Corp. on August 17, 1995 for $35 million. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Washington Biotechnology & Biomedical Association | |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |